Randomized trial validates hepatitis D prevalence in HBsAg-positive individuals, indicating updated health guidance is necessary.
To validate the accuracy of previously published US seroprevalence estimates for hepatitis D virus (HDV) antibody, we retested National Health and Nutrition Examination Survey samples from 2007‒2018 using a different assay. We found the HDV seroprevalence among hepatitis B surface antigen positive participants aged ≥6 years to be 1.26%.
No takes yet. Share an insight, caveat, or question.
Casillas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: